Scarica l'app Stockscreener
9.62
3.99%
-0.40
Dopo l'orario di chiusura:
9.50
-0.12
-1.25%
Precedente Chiudi:
$10.02
Aprire:
$10.25
Volume 24 ore:
66,086
Relative Volume:
0.26
Capitalizzazione di mercato:
$475.19M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-11.34%
1M Prestazione:
+20.70%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$9.57
$10.52
Intervallo di 1 settimana:
$8.77
$10.74
Portata 52W:
$6.71
$16.09
Maze Therapeutics Inc Stock (MAZE) Company Profile
Nome
Maze Therapeutics Inc
Settore
Industria
Telefono
(650) 850-5070
Indirizzo
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Confronta MAZE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
9.62 | 475.19M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Maze Therapeutics Inc Borsa (MAZE) Ultime notizie
Maze Therapeutics Inc (MAZE)’s Day in Review: Closing at 9.25, Up by 5.23 - DWinneX
Maze Therapeutics (NASDAQ:MAZE) versus Vaxcyte (NASDAQ:PCVX) Financial Survey - Defense World
Maze Therapeutics (NASDAQ:MAZE) Shares Down 19.4% – Here’s What Happened - Defense World
Greenbrier, RPM International, CVRx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Guggenheim Reiterates Buy Rating for Maze Therapeutics (NASDAQ:MAZE) - Defense World
Leerink Partnrs Has Bearish Forecast for MAZE Q1 Earnings - Defense World
Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights - GlobeNewswire
Maze Therapeutics reports Q4 EPS ($18.32) vs ($11.46) last year - TipRanks
Maze Therapeutics Inc. (MAZE) reports earnings - qz.com
Maze Therapeutics: Interesting Science But IPO-Related And Other Risks Exist (NASDAQ:MAZE) - Seeking Alpha
JOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Why Five Below Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket - Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Maze Therapeutics, Inc.’s (NASDAQ:MAZE) Quiet Period To End on March 12th - Defense World
Leerink Partners Begins Coverage on Maze Therapeutics (NASDAQ:MAZE) - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Stock Price Up 5.6%Still a Buy? - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Now Covered by Analysts at JPMorgan Chase & Co. - MarketBeat
Guggenheim Begins Coverage on Maze Therapeutics (NASDAQ:MAZE) - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Stock Rating Upgraded by Leerink Partnrs - MarketBeat
FY2024 Earnings Forecast for MAZE Issued By Leerink Partnrs - Defense World
Maze Therapeutics (NASDAQ:MAZE) Upgraded at TD Cowen - Defense World
FY2024 Earnings Estimate for MAZE Issued By Leerink Partnrs - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Coverage Initiated at JPMorgan Chase & Co. - Defense World
Maze Therapeutics (NASDAQ:MAZE) Coverage Initiated at Guggenheim - Defense World
Maze Therapeutics (NASDAQ:MAZE) Raised to “Strong-Buy” at Leerink Partnrs - Defense World
Maze Therapeutics initiated with a Buy at TD Cowen - TipRanks
Maze Therapeutics (NASDAQ:MAZE) Now Covered by Analysts at Leerink Partners - Defense World
Maze Therapeutics, Inc.: Buy Rating Backed by Promising Pipeline and Lead Asset MZE829 - TipRanks
Cowen initiates Maze Therapeutics stock with Buy rating By Investing.com - Investing.com Canada
Maze Therapeutics receives positive ratings following recent IPO - Investing.com
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Guggenheim sets $19 target on Maze Therapeutics stock By Investing.com - Investing.com Canada
Guggenheim Initiates Maze Therapeutics at Buy With $19 Price Target -February 25, 2025 at 06:43 am EST - Marketscreener.com
JPMorgan Initiates Maze Therapeutics at Overweight With $30 Price Target -February 25, 2025 at 06:32 am EST - Marketscreener.com
Promising Drug Candidates and Market Potential Drive Buy Rating for Maze Therapeutics - TipRanks
Maze Therapeutics initiated with an Outperform at Leerink - TipRanks
Maze Therapeutics: Strategic Positioning and Growth Potential in Genetic Disorders Market - TipRanks
JPMorgan sets Maze Therapeutics stock to Overweight with $30 target By Investing.com - Investing.com Canada
This New Drug Mimics The Health Effects of Living at High Altitude - ScienceAlert
Maze Therapeutics (NASDAQ:MAZE) Reaches New 12-Month LowShould You Sell? - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Hits New 12-Month Low – Here’s Why - Armenian Reporter
Maze Therapeutics (NASDAQ:MAZE) Shares Down 3.9%Here's Why - MarketBeat
Maze Therapeutics begins Phase 2 trial for kidney disease drug - MSN
Tesla, ON Semiconductor And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Maze Therapeutics doses first subject in Phase II AKD treatment trial - Yahoo Finance
Maze Therapeutics’ $140 Million Upsized Initial Public Offering - Global Legal Chronicle
Cyclo Therapeutics reports promising NPC1 treatment findings - MSN
Maze Therapeutics begins Phase 2 trial for kidney disease drug By Investing.com - Investing.com Australia
Maze Therapeutics Doses First Patient in Phase 2 HORIZON - GlobeNewswire
Groundbreaking Kidney Disease Trial: Maze's APOL1 Inhibitor Targets 1M+ Patient Market - StockTitan
Maze Therapeutics Inc Azioni (MAZE) Dati Finanziari
Non sono disponibili dati finanziari per Maze Therapeutics Inc (MAZE). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.84%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):